ライフサイエンスコーパス: pulmonary valve

1 lmonic stenosis, pulmonic atresia and absent pulmonary valve.

2 identified as that due to the absence of the pulmonary valve.

3 transcatheter placement of stents across the pulmonary valve.

4 the animals with stents placed distal to the pulmonary valve.

5 n's syndrome patients or those with unusable pulmonary valves.

6 tissue and isolated interstitial cells, than pulmonary valves.

7 rs frequently in aortic valves but rarely in pulmonary valves.

8 ctin-positive VICs in neonatal aortic versus pulmonary valves.

9 s, we isolated clonal populations from human pulmonary valves.

10 ineered valves reminiscent of that in native pulmonary valves.

11 e mitral and aortic but not the tricuspid or pulmonary valves, accompanied by inflammatory cell infil

12 RVCO calculated from blood flow through the pulmonary valve and from QDA and QP was good (r = .97, P

13 Nitinol stents were placed in the pulmonary valve and main pulmonary artery in five pigs b

14 ly resect the right posterior leaflet of the pulmonary valve and replace it with an engineered valve

15 such as transcatheter perforation of atretic pulmonary valves and endovascular stenting for coarctati

16 l technique, transcatheter implantation of a pulmonary valve, and outlines how real-time MRI in the n

17 Blood flows at the aortic and pulmonary valve annuli (LVCO and RVCO, respectively), ri

18 ons had a significantly higher occurrence of pulmonary valve atresia (P = 0.001) compared with cases

19 s and diminutive pulmonary arteries, initial pulmonary valve balloon dilation increases the annulus Z

20 for 10 such patients undergoing preoperative pulmonary valve balloon dilation, among other transcathe

21 th moderate neo-AI at discharge had abnormal pulmonary valves before surgery.

22 : Ebstein's anomaly, the failing Fontan, and pulmonary valve disease.

23 Fetal aortic and pulmonary valve; ductus arteriosus (DA); and right (RPA)

24 osus, 2 with tetralogy of Fallot, and 1 with pulmonary valve dysplasia.

25 peptide inhibitor reduced VEGF-induced human pulmonary valve endothelial cell proliferation, indicati

26 GF stimulates NFATc1 nuclear import in human pulmonary valve endothelial cells by a calcineurin-depen

27 monstrate that activation of NFATc1 in human pulmonary valve endothelial cells is specific to vascula

28 ted and translocated to the nucleus in human pulmonary valve endothelial cells to gain a better under

29 t is an emerging therapy intended to restore pulmonary valve function in patients with right ventricu

30 Preservation or restoration of pulmonary valve function may thus reduce the risk of sud

31 In HLHS, the pulmonary valve functions as the neo-aortic valve.

32 At most recent follow-up, the maximum pulmonary valve gradient by echocardiogram remained sign

33 of the novel Medtronic Harmony transcatheter pulmonary valve (hTPV) and to assess its effect on pulmo

34 ressure gradient acutely after transcatheter pulmonary valve implantation (39 versus 10 mm Hg; P<0.00

35 Percutaneous pulmonary valve implantation (PPVI) can treat this condi

36 Percutaneous pulmonary valve implantation (PPVI) has been developed a

37 Percutaneous pulmonary valve implantation (PPVI) is a safe, less inva

38 iological effects of BMS versus percutaneous pulmonary valve implantation (PPVI) using an x-ray/magne

39 within pediatric cardiology is percutaneous pulmonary valve implantation (PPVI).

40 of congenital heart disease had percutaneous pulmonary valve implantation (PPVI).

41 heart disease underwent Melody percutaneous pulmonary valve implantation at our institution.

42 e Melody device (Medtronic) for percutaneous pulmonary valve implantation experience stent fractures

43 f patients who underwent Melody percutaneous pulmonary valve implantation experienced subsequent BSI,

44 Percutaneous pulmonary valve implantation using a stent-based biopros

45 Transcatheter pulmonary valve implantation using the Melody valve has

46 Transcatheter pulmonary valve implantation using the Melody valve with

47 w the combined experience with transcatheter pulmonary valve implantation within BPVs from 8 centers

48 ed follow-up for patients after percutaneous pulmonary valve implantation.

49 ay be associated with BSI after percutaneous pulmonary valve implantation.

50 lacement of >/=1 stents before transcatheter pulmonary valve implantation.

51 scular nitinol stents were placed across the pulmonary valve in 6 young pigs to induce pulmonary regu

52 valve was affected in all 8 patients (73%), pulmonary valve in 7 (64%), and left sided valves in 4 (

53 The stent was placed distal to the pulmonary valve in four animals and across the pulmonary

54 lmonary valve in four animals and across the pulmonary valve in one animal.

55 rated that TVR with the Melody transcatheter pulmonary valve in properly selected patients is safe, e

56 aortic valve interstitial cells (AVICs) and pulmonary valve interstitial cells (PVICs) differ in exp

57 is, with selective absence of the aortic and pulmonary valves, leading to death in utero from congest

58 lymer construct was implanted to replace one pulmonary valve leaflet in the same juvenile animal from

59 Tc1 was detected in the endothelium of human pulmonary valve leaflets by immunohistochemistry.

60 Human aortic and pulmonary valve leaflets from the same heart were collec

61 rm effectiveness of the Melody transcatheter pulmonary valve (Medtronic, Inc., Minneapolis, Minnesota

62 stheses, 36 mechanical), and 157 underwent a pulmonary valve operation.

63 he potential to guide stent placement in the pulmonary valve or artery and to evaluate flow volume wi

64 Transcatheter pulmonary valve placement is an emerging therapy for pul

65 124 patients; in the other 12, transcatheter pulmonary valve placement was not attempted because of t

66 has recently been treated with transcatheter pulmonary valve placement.

67 In all animals, the TEL persisted in the pulmonary valve position after 8 to 10 weeks, and all po

68 n of these autologous tissue leaflets in the pulmonary valve position in a lamb model.

69 ar nitinol stents in the pulmonary artery or pulmonary valve position.

70 n of these autologous tissue leaflets in the pulmonary valve position.

71 Anatomic abnormalities of the pulmonary valve preclude its use as an autograft.

72 cedures, 1,375 PDA procedures, 270 "typical" pulmonary valve procedures, 305 aortic valve procedures,

73 Off-label use of transcatheter aortic and pulmonary valve prostheses for tricuspid valve-in-valve

74 were to determine the growth pattern of the pulmonary valve (PV) annulus and right heart structures

75 ates the contribution of infundibular versus pulmonary valve (PV) dysfunction on right ventricular (R

76 Percutaneous pulmonary valve (PV) replacement was successful in all p

77 LVOTO was defined as pulmonary valve (PV) z-score < or =-2.0 or LVOT gradient

78 edictive scores for specific gestations were pulmonary valve (PV) z-score (<23 weeks), median TV z-sc

79 haracteristically affects tricuspid (TV) and pulmonary valves (PV), and TV replacement is helpful in

80 lar end-diastolic dimensions and severity of pulmonary valve regurgitation.

81 Indications for surgical pulmonary valve replacement (PVR) after repair of tetral

82 Pulmonary valve replacement (PVR) after repair of tetral

83 The timing of pulmonary valve replacement (PVR) for free pulmonary inc

84 Pulmonary valve replacement (PVR) in patients with repai

85 Because the real benefit of pulmonary valve replacement (PVR) in patients with repai

86 Pulmonary valve replacement (PVR) in repaired tetralogy

87 Although pulmonary valve replacement (PVR) is effective in reduci

88 ts with repaired tetralogy of Fallot require pulmonary valve replacement (PVR), but the evaluation fo

89 for Ebstein's anomaly, Fontan revision, and pulmonary valve replacement (PVR).

90 Transcatheter pulmonary valve replacement (TPVR) has become a useful t

91 Transcatheter pulmonary valve replacement (TPVR) is an established the

92 Follow-up of transcatheter pulmonary valve replacement (TPVR) with the Melody valve

93 Percutaneous pulmonary valve replacement has recently opened new pers

94 tricuspid valve replacement in all patients, pulmonary valve replacement in 3 and valvectomy in 7, mi

95 y offer an alternative for standard surgical pulmonary valve replacement in dilated right ventricular

96 w tracts, permitting lower risk, nonsurgical pulmonary valve replacement in previously prohibitive an

97 Transcatheter pulmonary valve replacement is evolving, but to date, ex

98 icant PR with RV dilation, optimal timing of pulmonary valve replacement remains uncertain, although

99 ongenital heart disease (CHD), transcatheter pulmonary valve replacement represents a transformative

100 Pulmonary valve replacement should be performed before t

101 Transcatheter pulmonary valve replacement using the Edwards SAPIEN tra

102 e remodeling (QRS fragmentation and previous pulmonary valve replacement) (+2.7%; 95% confidence inte

103 underwent mitral and tricuspid valve repair, pulmonary valve replacement, and a maze procedure (the l

104 ps with symptoms, restrictive RV, RV EF<40%, pulmonary valve replacement, or QRS fragmentation.

105 effect on TR, as is often seen with surgical pulmonary valve replacement.

106 ncluding RVOT reconstruction, at the time of pulmonary valve replacement.

107 lves (TEHVs) was evaluated up to 24 weeks as pulmonary valve replacements (transapical access) in she

108 The most prominent cardiac defects in NS are pulmonary valve stenosis and hypertrophic cardiomyopathy

109 r septal defects, atrial septal defects, and pulmonary valve stenosis) occurred in 2.0 per 1000 birth

110 graphic abnormalities, ocular hypertelorism, pulmonary valve stenosis, abnormal genitalia, retardatio

111 gen dioxide and coarctation of the aorta and pulmonary valve stenosis.

112 The incidence of Melody transcatheter pulmonary valve stent fracture (3.4%) and infectious end

113 mined from points assigned for tricuspid and pulmonary valve structure and function.

114 mmon atrioventricular canal (n = 17), absent pulmonary valve syndrome (n = 24) and aortopulmonary win

115 8) of fetuses with TOF, excluding the absent pulmonary valve syndrome, survived.

116 the animal with the stent placed across the pulmonary valve, the pulmonary regurgitant fraction was

117 In 2010, the Melody transcatheter pulmonary valve (TPV) received Food and Drug Administrat

118 Transcatheter (percutaneous) pulmonary valve (TPV) replacement has emerged as a viabl

119 Transcatheter pulmonary valve (TPV) replacement is an emerging therapy

120 Melody Transcatheter Pulmonary Valve (TPV) replacement therapy represents an

121 Studies of transcatheter pulmonary valve (TPV) replacement with the Melody valve

122 The Melody transcatheter pulmonary valve (TPV) was approved for implantation in o

123 he aortic arch, dysgenesis of the aortic and pulmonary valves, ventricular septal defects, and other

124 y bypass, the right posterior leaflet of the pulmonary valve was completely resected and replaced wit

125 ore hemodynamic and 3D ultrasonic study, the pulmonary valve was excised from 6 sheep (31 to 59 kg) t

126 The pulmonary valve was first balloon dilated (mean balloon/

127 The pulmonary valve was replaced in 33 cases (59) and the tr